ALFA Finder
The call has ended.
Key takeaways
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | Revenue +27.9% YoY to ₹85.4 Cr; no one-offs stated. |
|---|---|
| Margins | EBITDA 21.5% (−50bps), PAT 14.1% (−90bps) YoY; contracting. |
| Demand visibility | Management cites strong demand; declined to disclose order book. |
| Management confidence | Balanced to defensive; frequent 'we'll try' and 'not advised' hedges. |
Growth
Revenue +27.9% vs EBITDA +25.2% and PAT +20%, so profit lags sales. Nutraceuticals (₹75.3 Cr, ~88% of sales) drive growth, while margins fell (EBITDA 21.5%, −50bps; PAT 14.1%, −90bps).
Outlook
Guides 25% FY27 growth, but the new plant is only 'a couple of months' from operational. Its H2 contribution (~20%) is hedged and conditional on licensing.
Risks
Capex-heavy funding gap (₹19.9 Cr capex vs ₹7.2 Cr operating cash). Top three clients ~25–30% of revenue. Management deflected margin, order book and run-rate questions.
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Influx Healthtech H1 FY27 Results: Net Profit ₹12 Cr, Up 20.0% YoY
Influx Healthtech Ltd reported revenue from operations of ₹85.4 Cr (+27.8% YoY) and net profit of ₹12 Cr (+20.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹12 Cr · +20.0% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Guidance of 25-30% minimum growth for FY27; long-term target of ₹500cr revenue by FY29.
Growth they described
FY26 Revenue up 41% to ₹146cr; EBITDA up 32% to ₹29.9cr; PAT grew to ₹20.5cr (14% margin).
Call details
| Company | Influx Healthtech Limited |
|---|---|
| NSE symbol | INFLUX |
| ISIN | INE0MYZ01012 |
| Call | Q2 FY27 earnings call |
| Date | Thursday, 5 November 2026 |
| Time | 1:30 PM IST |
Influx Healthtech Limited: key numbers
- Share price
- ₹251.00
- Market cap
- ₹581.1 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 28.3×Sector 43.0×
- Promoter holding
- 73.53%
- FII holding
- 0.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Thu, 5 Nov
Today's concalls →
